The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review

Abstract

B‐cell malignancies, most notably lymphomas, make up most of the non‐Hodgkin lymphomas in the United States. There are limited randomized data comparing first‐ and second‐generation Bruton tyrosine kinase (BTK) inhibitors. Our aim was to compare the safety profiles of first versus second‐generation BTK inhibitors. A systematic search was performed from database inception to January 13, 2020. Studies with BTK inhibitor monotherapy for the treatment of B‐cell malignancies in the adult population (>18 years old) were utilized and the adverse events (AEs) were extracted. Fifty‐five studies that met the inclusion criteria were included in the systematic review with 41 studies with first generation and 14 studies with second generation. The review included both clinical trials and retrospective studies with average time of follow‐up of 2 years for the first‐generation group and 18 months for the second‐generation group. We found that the incidence of cardiovascular AEs was significantly higher in the first‐generation group (20.8%) as compared to the second‐generation group (6.3%). However, there was a higher incidence of hematologic/oncologic and gastrointestinal side effects in the second‐generation group compared to the first (62.3% compared to 39.2% and 36.9% compared to 28.9%). The number of Grade 5 cardiovascular events (death) was same in the first‐generation group compared to the second generation. Further research is needed to develop highly selective BTK inhibitors to avoid unwanted AEs by minimizing off‐targets.

Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future

“…The second generation BTK inhibitors were introduced to reduce BTK-related cardiotoxicity. In this generation, adverse effect occur in 6.3% vs. 20.8% cases in first generation ( 202 ). Although according to Arustamyan et al ( 202 ), the second generation BTK inhibitors have increased incidence of other adverse effects such as endocrine, gastrointestinal, neurological etc.…”

“…In this generation, adverse effect occur in 6.3% vs. 20.8% cases in first generation ( 202 ). Although according to Arustamyan et al ( 202 ), the second generation BTK inhibitors have increased incidence of other adverse effects such as endocrine, gastrointestinal, neurological etc. Pirtobrutinib is highly selective BTK inhibitor and is classified as third generation.…”